Skip to content
GLP-1 Clinics Nearby
Compounding explainedJuly 24, 2026 · 10 min read

Compounded GLP-1 medications: what “not FDA approved” means

Compounded semaglutide and tirzepatide are not FDA-approved generic versions of branded drugs. FDA does not review them for safety, effectiveness, or quality before marketing.

Edited by

· Co-founder & CTO, Savo Group

B.S. in Computer Science, Oregon State University · B.A. in Psychology, University of Washington, Seattle

Compounded GLP-1 pharmacy quality check of an unbranded medication vial

Current status

Not FDA approved

Compounding can have a role for an identified patient need, but the current legal and safety context matters.

FDA approved
No
Same as a generic
No
Ask for
The dispensing pharmacy
At a glance

Approved, compounded, and research-grade are different categories

Marketing can place these terms side by side even though their review, labeling, and legitimate uses differ.

Swipe horizontally to compare →

Approved, compounded, and research-grade are different categories. Marketing can place these terms side by side even though their review, labeling, and legitimate uses differ.
CategoryFDA premarket reviewConsumer question
FDA-approved productReviewed for the approved product and labeled useWhich exact product and indication are prescribed?
Compounded drugNot FDA approved before marketingWhat patient need, prescriber, compounder, and label support this use?
Research-grade productNot an approved patient treatmentWhy is a seller presenting a research product for human use?

Table source:FDA concerns with unapproved GLP-1 drugs

01

Compounded is not the same as generic

A generic drug has been reviewed and approved by FDA. A compounded drug is prepared for a patient under specific sections of federal and state law and is not FDA approved. FDA does not conduct premarket review of a compounded product’s safety, effectiveness, or quality.

Marketing that implies a compounded preparation is “the same as,” “generic for,” or an FDA-approved version of a branded GLP-1 product can erase a distinction readers need in order to compare offers accurately.

02

The shortage-era market has changed

FDA states that semaglutide and tirzepatide do not currently appear on the FDA drug shortage list. The agency has also clarified that certain conditions must be met for compounded drugs to qualify for exemptions from standard approval requirements.

In April 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them from bulk drug substances. Rules and enforcement can change, so programs should not rely on old shortage language.

03

FDA has identified product, marketing, and dosing concerns

FDA reports concerns involving fraudulent labels, improper storage during shipping, salt forms of semaglutide, adverse-event reports, misleading claims, and dosing errors. It has also warned telehealth companies about marketing compounded drugs as equivalent to approved brands.

FDA says compounded drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved drug and recommends filling prescriptions at state-licensed pharmacies.

Retatrutide cannot be used in compounding under federal law. A clinic or website selling “compounded retatrutide” should not appear as a legitimate treatment option.

04

Questions to ask before paying a compounded-medication program

The provider and pharmacy should be named clearly. The label, concentration, measuring device, storage, shipping, adverse-event contact, and total price should be understandable before medication is used.

  • What specific medical need makes compounding appropriate in my case?
  • Which licensed clinician is responsible for the prescription?
  • Which state-licensed pharmacy dispenses the medication?
  • What exactly appears on the prescription and product label?
  • How are concentration, measurement, refrigeration, and shipping explained?
  • What is the complete recurring price and how do I reach clinical support?

Common questions

Answers to clarify the comparison

Is compounded semaglutide FDA approved?
No. Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness, or quality before marketing.
Is compounded tirzepatide a generic Zepbound?
No. A compounded drug is not an FDA-approved generic version of Zepbound or Mounjaro.
Can retatrutide be compounded?
FDA states that retatrutide cannot be used in compounding under federal law.

Primary sources

Read the official material behind this page

Health information is educational and does not diagnose, determine eligibility, or replace product labeling and care from a qualified professional.